Fabrication of Spanlastics as a potential transdermal delivery of lornoxicam for efficient management of osteoarthritis and side effect mitigation: Formula optimization, in vitro characterization, ex vivo, and in vivo assessments.

El-Dahmy RM, El-Mallahy NM, Teaima MH, Awny MM, El-Mancy SS

Open source

DOI
10.1016/j.ijpharm.2026.127140
Published
2026 Aug 10
Container
International journal of pharmaceutics
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.ijpharm.2026.127140,
  title = {Fabrication of Spanlastics as a potential transdermal delivery of lornoxicam for efficient management of osteoarthritis and side effect mitigation: Formula optimization, in vitro characterization, ex vivo, and in vivo assessments.},
  author = {El-Dahmy RM and El-Mallahy NM and Teaima MH and Awny MM and El-Mancy SS},
  year = {2026},
  journal = {International journal of pharmaceutics},
  doi = {10.1016/j.ijpharm.2026.127140},
  url = {https://doi.org/10.1016/j.ijpharm.2026.127140}
}

RIS

TY  - JOUR
TI  - Fabrication of Spanlastics as a potential transdermal delivery of lornoxicam for efficient management of osteoarthritis and side effect mitigation: Formula optimization, in vitro characterization, ex vivo, and in vivo assessments.
AU  - El-Dahmy RM
AU  - El-Mallahy NM
AU  - Teaima MH
AU  - Awny MM
AU  - El-Mancy SS
PY  - 2026
JO  - International journal of pharmaceutics
DO  - 10.1016/j.ijpharm.2026.127140
UR  - https://doi.org/10.1016/j.ijpharm.2026.127140
ER  - 

APA

RM, E., NM, E., MH, T., MM, A., & SS, E. (2026). Fabrication of Spanlastics as a potential transdermal delivery of lornoxicam for efficient management of osteoarthritis and side effect mitigation: Formula optimization, in vitro characterization, ex vivo, and in vivo assessments.. International journal of pharmaceutics. https://doi.org/10.1016/j.ijpharm.2026.127140

Source records